Tactile Systems Technology Inc (Tactile Medical) develops, manufactures, markets, and distributes medical devices for the treatment of chronic vascular diseases at home. The company’s proprietary products advance the standard of care for the treatment of lymphedema and chronic venous insufficiency. The company classifies its business operations into two product categories, namely, the Lymphedema and Airway Clearance. Tactile Medical's primary activities include the development, manufacturing, and distribution of at-home healthcare solutions. Tactile Medical distributes its products based on the direct-to-patient and provider model. It distributes its products directly to customers through a direct sales force. Its direct-to-patient model includes direct sales force, contracts with at-home trainers, reimbursement capabilities and medical expertise to expand awareness. The company operates primarily in the US and serves the healthcare industry, including vascular surgeons, oncology care teams, and respiratory therapists. The company also utilizes a durable medical equipment (DME) distribution model for its respiratory therapy products. Tactile Medical has its manufacturing activities located in Minneapolis, Minnesota, where it conducts quality inspection, assembly, packaging, warehousing, and shipping of its products.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

The company’s R&D focuses on the innovation and development of advanced products for the customers in the area of chronic disease, especially lymphedema, cancer-related lymphedema, chronic venous insufficiency, bronchiectasis and other chronic respiratory conditions. Its development activities include the scientists, clinical monitors and project managers with expertise in pneumatics, electronics, garment design, embedded software, mechanical design, sensors, manufacturing technologies and clinical trial management. It focuses on providing increasing efficacy, enhancing design for ease-of-use, improving clinical functionality and lowering production costs of its solutions. In FY2024, the company spent US$8.8 million on its R&D activities, which as a percentage of revenue stood at 3% and grew 12.8% YoY. As of December 2024, the company owned 171 issued patents globally, including 65 issued US patents. It also consists of 240 pending patent applications, of which nine are pending patent applications in the US. It owns US patents from 2025 to 2040.